Evidence map›Paper›PMID 34272712›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2021

Case Study 5: Predicting the Drug Interaction Potential for Inhibition of CYP2C8 by Montelukast.

Ken Korzekwa

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 89% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Ken KorzekwaDepartment of Pharmaceutical Sciences, Temple University School of Pharmacy, Philadelphia, PA, USA. korzekwa@temple.edu.
Temple University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Predicting drug-drug interactions (DDIs) from in vitro data is made difficult by not knowing concentrations of substrate and inhibitor at the target site. For in vivo targets, this is understandable, since intracellular concentrations can differ from extracellular concentrations. More vexing is that the concentration of the drug at the target for some in vitro assays can also be unknown. This uncertainty has resulted in standard in vitro practices that cannot accurately predict human pharmacokinetics. This case study highlights the impact of drug distribution, both in vitro and in vivo, with the example of the drug interaction potential of montelukast.

Indexed as

AcetatesArea Under CurveCyclopropanesCytochrome P-450 CYP2C8Drug InteractionsHumansKineticsPlasmaQuinolinesRosiglitazoneSulfidesAcetatesCyclopropanesCYP2C8 protein, humanCytochrome P-450 CYP2C8montelukastQuinolinesRosiglitazoneSulfidesCheng-Prusoff equationCYP2C8Drug-drug interactionFraction unboundFree drug hypothesisMicrosomal proteinsMontelukastProtein binding

Identifiers

PMID34272712
OpenAlexW3178107477

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.